Henric from Finland

Registered at the short selling broker Skilling, 3 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Sanofi (SNY) shares information


24h Change

-2.67 %


Live rate: Market closed

Stock data per Tuesday 4 Aug, 2020

-1.42 (-2.67%)
US Market is closed

Live Stock price in graph for Sanofi (SNY)

  • Latest Volume

    1,274,476 (8.29 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high


  • 52 week low


  • YTD Change

    + 0.82 %

Quick links

Broker recommendations for Sanofi

The Sanofi stock is rated at 1.409091 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 25 June, 2020 by a total of 22 brokers. This means that the consensus of the 22 different brokers is leaning toward to buy/moderate buy.

0 (0%)
0 (0%)
8 (36.36%)
2 (9.09%)
12 (54.55%)

Price target by analysts

The 19 latest analyst estimates, per Monday 3 August, 2020, show the following high, low and average price targets.
Target Average: 60.98 USD
Target High: 65.35 USD
Target Low: 50.26 USD


Latest news about Sanofi

Below you can find the most recent news posts about Sanofi, primarily from US and UK based news sources.

Drug giants in talks over vaccine volumes

Tuesday, 4 August 2020, 07:00:00
DRUG giants Sanofi and GlaxoSmithKline are in advanced discussions with the European Commission for the supply of up to 300 million doses of a…
— Herald Scotland

DOJ probes Sanofi, GSK over possible carcinogen in Zantac

Monday, 3 August 2020, 18:04:38
The theory is the drugs should not have been reimbursed by the government if they were unapproved, misbranded or adulterated, an expert said.
— STAT News

French firm Sanofi indicted over epilepsy drug

Monday, 3 August 2020, 14:19:24
The pharmaceutical giant is accused of manslaughter after babies died, but it denies wrongdoing.

GSK and Sanofi in ‘advanced discussions’ with EU over Covid-19 vaccine

Monday, 3 August 2020, 13:22:00
Drugs giants GlaxoSmithKline and Sanofi today neared the completed a trio of key agreements to supply their Covid-19 vaccine, amid discussions with the EU. The pair said they are in “advanced discussions” with the European bloc to supply 300 million doses of their candidate, which uses Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
— Evening Standard

Sanofi under investigation on charges including manslaughter over Depakine

Monday, 3 August 2020, 12:57:00
Sanofi Aventis France added it had respected all its obligations regarding information provided on Depakine
— Business Standard